Preliminary data from a clinical trial (phase 2) of an acellular pertussis vaccine, J-NIH-6.
In the search for a new and better pertussis vaccine for general vaccination in Sweden, a clinical trial of an adsorbed acellular vaccine from Japan has been performed. The vaccine used was produced by Biken and contained only F-HA and the toxoid of pertussis toxin (LPF). The aims were: To demonstrate the serological response to primary vaccination of this adsorbed acellular vaccine in comparison to a plain whole cell vaccine. To compare the incidence of side reactions between the two types of vaccines and the adjuvant (aluminium phosphate) of the acellular vaccine used as placebo.
D000276:Adjuvants, Immunologic / Q000009:adverse effects; D000535:Aluminum / Q000009:adverse effects; D017607:Aluminum Compounds; D000992:Antitoxins / Q000032:analysis*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D006801:Humans; D007223:Infant; D037342:Pertussis Toxin; D010567:Pertussis Vaccine / Q000009:adverse effects / Q000276:immunology*; D010710:Phosphates / Q000009:adverse effects; D011897:Random Allocation; D014611:Vaccination; D010566:Virulence Factors, Bordetella / Q000276:immunology*
D000276:Adjuvants, Immunologic; D017607:Aluminum Compounds; D000992:Antitoxins; D010567:Pertussis Vaccine; D010710:Phosphates; D010566:Virulence Factors, Bordetella; D000535:Aluminum; D037342:Pertussis Toxin; C012714:aluminum phosphate